ZIKALIVAX 2.0 (Q3712907): Difference between revisions
Jump to navigation
Jump to search
(Created claim: summary (P836): The postdoctoral research aims at experimentally validating the attenuated viral strain ZIKALIVax as a live vaccine candidate against ZIKA fever., translated_summary) |
(Changed label, description and/or aliases in en: translated_label) |
||
| label / en | label / en | ||
ZIKALIVAX 2.0 | |||
Revision as of 14:07, 22 November 2021
Project Q3712907 in France
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | ZIKALIVAX 2.0 |
Project Q3712907 in France |
Statements
63,811.94 Euro
0 references
99,706.15 Euro
0 references
64.0 percent
0 references
1 September 2017
0 references
31 August 2019
0 references
UNIVERSITÉ DE LA RÉUNION
0 references
Les travaux menés par le post-doctorant visent à valider expérimentalement la souche virale atténuée ZIKALIVax comme un candidat vaccin vivant contre la fièvre ZIKA. (French)
0 references
The postdoctoral research aims at experimentally validating the attenuated viral strain ZIKALIVax as a live vaccine candidate against ZIKA fever. (English)
22 November 2021
0 references
Identifiers
RE0012406
0 references